CD274 and non-small cell lung carcinoma: In an open‐label phase‐III clinical trial, treatment‐naïve advanced NSCLC patients with greater than 50% PD‐L1 tumor cell expression (n = 305) demonstrated significantly longer progression‐free (10.3 months vs 6.0 months) and 6‐month overall survival (80.2% vs 72.4%), with fewer adverse events when treated with pembrolizumab compared to first‐line platinum‐based chemotherapies.41 This study led to the FDA approving pembrolizumab as first‐line treatment for patients with a tumor proportion score for PD‐L1 of 50% or greater.